Zevra Therapeutics
ZVRA
33 hedge funds and large institutions have $24.4M invested in Zevra Therapeutics in 2018 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 9 reducing their positions, and 14 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9.67% less ownership
Funds ownership: 41.43% → 31.75% (-9.7%)
18% less funds holding
Funds holding: 40 → 33 (-7)
44% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 9
50% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 14
76% less capital inflows, than outflows
Capital inflows: $2.29M | Capital outflows: $9.62M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DA
DSC Advisors
Chicago,
Illinois
|
+$1.49M |
| 2 |
Bridgeway Capital Management
Houston,
Texas
|
+$269K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$199K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$146K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$62.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
C WorldWide Group
Copenhagen,
Denmark
|
-$2.6M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.6M |
| 3 |
Millennium Management
New York
|
-$983K |
| 4 |
JP Morgan Chase
New York
|
-$876K |
| 5 |
PVI
Pura Vida Investments
New York
|
-$390K |
ZVRA Hedge Fund Activity: Q3 2018 in Review
33 of the 4,392 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q3 2018, worth a combined $24.4M — down 40% from $40.8M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of ZVRA and 7 opened new positions — a net loss of 7 holders — while 9 trimmed existing stakes and 5 added.
The largest buyer was DSC Advisors, adding an estimated $1.49M. The largest seller was C WorldWide Group, exiting entirely with an estimated $2.6M sold.
- 33 institutional investors held Zevra Therapeutics (ZVRA) as of Q3 2018, down from 40 in Q2 2018.
- Funds reported $24.4M of Zevra Therapeutics stock for Q3 2018, down 40% quarter-over-quarter.
- 7 funds opened new Zevra Therapeutics positions in Q3 2018 and 14 closed out, a net change of -7 holders.
- The largest Zevra Therapeutics buyer in Q3 2018 was DSC Advisors, an estimated $1.49M added.
- The largest Zevra Therapeutics seller in Q3 2018 was C WorldWide Group, an estimated $2.6M sold.
Based on aggregated 13F filings for Q3 2018.